Clinical Trial Detail

NCT ID NCT03041181
Title Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nasser Hanna, M.D.
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + Nivolumab

Docetaxel

Age Groups: adult senior

No variant requirements are available.